Drugs / Temferon
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06716853 | Oct 2024 → Jan 2026 | clear cell renal carcinoma | Genenta Science | Terminated | No outcome recorded |
| Phase 1/2 | NCT03875495 | Mar 2019 → Apr 2021 | plasma cell myeloma | Genenta Science | Terminated | No outcome recorded |
| Phase 1/2 | NCT03866109 | Mar 2019 → May 2026 | glioblastoma | Genenta Science | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Temferon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03875495 ↗ |
| Action | Restore | “driving myeloid specific interferon-alpha2 expression” NCT03866109 ↗ |
| Modality | Cell therapy | “autologous CD34+-enriched hematopoietic stem and progenitor cells” NCT03866109 ↗ |
| Route | Intravenous | “single intravenous infusion of Temferon” NCT03875495 ↗ |